Literature DB >> 24437734

Urinary metabolic fingerprint of acute intermittent porphyria analyzed by (1)H NMR spectroscopy.

Mickael Carichon1, Nicolas Pallet, Caroline Schmitt, Thibaud Lefebvre, Laurent Gouya, Neila Talbi, Jean Charles Deybach, Philippe Beaune, Paul Vasos, Hervé Puy, Gildas Bertho.   

Abstract

(1)H NMR is a nonbiased technique for the quantification of small molecules that could result in the identification and characterization of potential biomarkers with prognostic value and contribute to better understand pathophysiology of diseases. In this study, we used (1)H NMR spectroscopy to analyze the urinary metabolome of patients with acute intermittent porphyria (AIP), an inherited metabolic disorder of heme biosynthesis in which an accumulation of the heme precursors 5-aminolaevulinic acid (ALA) and porphobilinogen (PBG) promotes sudden neurovisceral attacks, which can be life-threatening. Our objectives were (1) to demonstrate the usefulness of (1)H NMR to identify and quantify ALA and PBG in urines from AIP patients and (2) to identify metabolites that would predict the response to AIP crisis treatment and reflect differential metabolic reprogramming. Our results indicate that (1)H NMR can help to diagnose AIP attacks based on the identification of ALA and PBG. We also show that glycin concentration increases in urines from patients with frequent recurrences at the end of the treatment, after an initial decrease, whereas PBG concentration remains low. Although the reasons for this altered are elusive, these findings indicate that a glycin metabolic reprogramming occurs in AIPr patients and is associated with recurrence. Our results validate the proof of concept of the usefulness of (1)H NMR spectroscopy in clinical chemistry for the diagnosis of acute attack of AIP and identify urinary glycin as a potential marker of recurrence of AIP acute attacks.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24437734     DOI: 10.1021/ac403837r

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  7 in total

1.  Derivative Matrix-Isopotential Synchronous Spectrofluorimetry and Hantzsch Reaction: A Direct Route to Simultaneous Determination of Urinary δ-Aminolevulinic Acid and Porphobilinogen.

Authors:  Muhammad Ajmal; Jia-Wen Wei; Yan Zhao; Yi-Hong Liu; Ping-Ping Wu; Yao-Qun Li
Journal:  Front Chem       Date:  2022-05-31       Impact factor: 5.545

2.  Mass-spectrometric profiling of porphyrins in complex biological samples with fundamental, toxicological, and pharmacological applications.

Authors:  Sarah A Sullivan; Bennett R Streit; Ethan L Ferguson; Paul A Jean; Debra A McNett; Louis T Llames; Jennifer L DuBois
Journal:  Anal Biochem       Date:  2015-03-10       Impact factor: 3.365

3.  The metabolomics of psoriatic disease.

Authors:  Di Yan; Ladan Afifi; Caleb Jeon; Megha Trivedi; Hsin Wen Chang; Kristina Lee; Wilson Liao
Journal:  Psoriasis (Auckl)       Date:  2017-01-31

4.  Profiling of Serum Metabolites of Acute Intermittent Porphyria and Asymptomatic HMBS Mutation Carriers.

Authors:  Chia-Ni Lin; Ming-Shi Shiao; Mei-Ling Cheng; Chiung-Mei Chen; Hung-Chou Kuo
Journal:  Cells       Date:  2021-09-28       Impact factor: 6.600

Review 5.  Therapy Follows Diagnosis: Old and New Approaches for the Treatment of Acute Porphyrias, What We Know and What We Should Know.

Authors:  Petro E Petrides
Journal:  Diagnostics (Basel)       Date:  2022-07-03

6.  Urinary metabolic profiling of asymptomatic acute intermittent porphyria using a rule-mining-based algorithm.

Authors:  Margaux Luck; Caroline Schmitt; Neila Talbi; Laurent Gouya; Cédric Caradeuc; Hervé Puy; Gildas Bertho; Nicolas Pallet
Journal:  Metabolomics       Date:  2017-12-04       Impact factor: 4.290

7.  Evaluation of Metabolic Changes in Acute Intermittent Porphyria Patients by Targeted Metabolomics.

Authors:  Alex Gomez-Gomez; Paula Aguilera; Klaus Langohr; Gregori Casals; Cristina Pavon; Josep Marcos; Jordi To-Figueras; Oscar J Pozo
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.